Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease

Next Previous
Trial Profile

A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Sponsors Keryx Biopharmaceuticals

Most Recent Events

  • 04 Apr 2018 Results published in the Keryx Biopharmaceuticals Media Release
  • 04 Apr 2018 According to Keryx Biopharmaceuticals media release, post-hoc data from this study is published in the online issue of the American Journal of Hematology.
  • 07 Nov 2017 According to Keryx Biopharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved Auryxia for the treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis. The sNDA was based on data from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top